Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $19.48 USD
Change Today -0.20 / -1.02%
Volume 418.8K
AEGR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

aegerion pharmaceuticals inc (AEGR) Snapshot

Open
$19.59
Previous Close
$19.68
Day High
$19.81
Day Low
$19.35
52 Week High
07/30/14 - $36.68
52 Week Low
10/31/14 - $19.10
Market Cap
556.6M
Average Volume 10 Days
637.1K
EPS TTM
$-1.37
Shares Outstanding
28.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AEGERION PHARMACEUTICALS INC (AEGR)

aegerion pharmaceuticals inc (AEGR) Related Businessweek News

No Related Businessweek News Found

aegerion pharmaceuticals inc (AEGR) Details

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products include JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults. Its products also comprise MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The company distributes its products directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

301 Employees
Last Reported Date: 05/8/15
Founded in 2005

aegerion pharmaceuticals inc (AEGR) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $635.0K
Chief Operating Officer
Total Annual Compensation: $385.8K
Chief Medical Officer
Total Annual Compensation: $405.0K
Chief Performance Officer
Total Annual Compensation: $341.3K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

aegerion pharmaceuticals inc (AEGR) Key Developments

Aegerion Pharmaceuticals Achieves Primary Endpoint in Phase III Study of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia

Aegerion Pharmaceuticals, Inc. announced the primary endpoint was achieved in the company's open-label, multicenter study to evaluate the efficacy and safety of lomitapide in nine Japanese patients with homozygous familial hypercholesterolemia (HoFH). The primary endpoint measured mean percent change in low-density lipoprotein cholesterol (LDL-C) at the maximum tolerated dose compared to baseline after 26 weeks of treatment, in combination with other lipid-lowering therapy. Following the 26 week assessment, patients in the study entered a 30-week safety phase. Each patient will continue receiving the maximum tolerated dose of lomitapide he or she achieved during the efficacy phase for an additional 30 weeks in the safety phase, subject to safety-related dose adjustments. The company expects to file the NDA in Japan with the 26-week data, and to submit the 56-week data during the review cycle.

Aegerion Pharmaceuticals, Inc. Announces Executive Changes

Aegerion Pharmaceuticals, Inc. announced that Mark Fitzpatrick, Aegerion's chief financial officer (CFO), has resigned. David Aubuchon, Aegerion's chief accounting officer, will serve as acting CFO in the interim. The transition between Mr. Fitzpatrick and Mr. Aubuchon will occur within the next 30 days. David Aubuchon has served as chief accounting officer of Aegerion since March of 2015. Prior to joining the Company, Mr. Aubuchon was corporate controller at Ocata Therapeutics since October 2013 and was corporate controller at Inspiration Biopharmaceuticals from July 2012 until December 2012.

Aegerion Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Fiscal Year 2015

Aegerion Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's net product sales were $59,384,000 compared to $26,973,000 a year ago. Loss from operations was $9,180,000 compared to $15,374,000 a year ago. Loss before provision for income taxes was $15,626,000 compared to $15,776,000 a year ago. Net loss was $15,825,000 or $0.55 per basic and diluted share compared to $15,776,000 or $0.54 per basic and diluted share a year ago. Non-GAAP net income was $1,577,000 or $0.06 per basic and diluted share compared to net loss of $7,248,000 or $0.25 per basic and diluted share a year ago. For the full year of 2015, the company now expects global net product sales of JUXTAPID to be between $195 million and $215 million, global net product sales of MYALEPT to be between $10 million and $20 million, total non-GAAP operating expenses of between $195 million and $205 million. The Company's non-GAAP operating expenses exclude the impact of expected stock-based compensation expenses of between $30 million and $40 million and the purchase price accounting effects related to the preliminary fair value of assets acquired in the MYALEPT acquisition, generate positive cash flow from operations for the full year of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEGR:US $19.48 USD -0.20

AEGR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Isis Pharmaceuticals Inc $67.32 USD +0.61
View Industry Companies
 

Industry Analysis

AEGR

Industry Average

Valuation AEGR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEGERION PHARMACEUTICALS INC, please visit www.aegerion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.